Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children

Bone Marrow Transplantation

Volumn 18, Issue 2, 1996, Pages 377-382

  Gerritsen, E J A ^a,e   Stam, E D ^a   Hermans, J ^b   Van Den Berg, H ^a,c   Haraldsson, A ^a,d   Van Tol, M J D ^a   Langlois Van Den Bergh, R ^a   Waaijer, J L M ^a   Kroes, A C M ^a   Kluin, P M ^a   Vossen, J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

B cell lymphoma; BMT; Children; Risk factors

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EPSTEIN BARR VIRUS; GENOTYPE; HLA MATCHING; HUMAN; INFANT; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; ROSETTE FORMATION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LYMPHOMA, B-CELL; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 9444232751     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vossen JMJJ. Bone marrow transplantation in children. In: Broyer M (ed). Baillière's Clinical Paediatrics. Baillière Tindall: London, 1993, pp 1029-1059.
2. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantations from related donors other than HLA-identical siblings. New Engl J Med 1985; 313: 197-204.
3. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. New Engl J Med 1993; 328: 593-602.
4. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
5. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
6. Gerritsen EJA, Stam ED, Hermans J et al. Follow-up of leucocyte and reticulocyte counts for the prediction of early graft failure after non HLA-identical BMT in children. Bone Marrow Transplant 1996; 17: 781-787.
7. Hale G, Waldmann M. Campath-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15-31.
8. Fischer A, Friedrich W, Fasth A et al. Reduction of graft failure by a monoclonal antibody (anti-LFAl CD11a) after HLA non-identical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for bone marrow transplantation report. Blood 1991; 77: 249-256.
9. Jabado N, Deist F Le, Cant A et al. Bone marrow transplantation from genetically HLA-non identical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics 1996 (in press).
10. Kaminski E, Hows J, Man S et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T-cells after unrelated donor bone marrow transplantation. Transplantation 1989; 48: 608-613.
11. Wagemaker G, Heidt PJ, Merchav S, Bekkum DW van. Abrogation of histo-incompatibility barriers in Rhesus monkeys. In. Baum SJ, Ledney GD, Thierfelder S (eds). Experimental Haematalogy Today Karger: Basel, 1982, pp 111-118.
12. Vossen JM, Heidt PJ, Berg H van den et al. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23.
13. Belanger C, Esperou-Bourdeau H, Bordigoni P et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993; 11: 293-297.
14. Shapiro R, Chauvenet A, McGuire W et al. Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gammaglobulin. New Engl J Med 1988; 318: 1334 (letter).
15. Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. New Engl J Med 1991; 324: 1451-1456.
16. Hekman A, Honselaar A, Vuist WMJ et al. Initial experience of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991; 32: 364-372.
17. Brown N, Smith D, Miller G et al. Infectious mononucleosis: a polyclonal B-cell transformation in vivo. J Infect Dis 1984; 150: 517-522.
18. Rickinson AB, Wallace LE, Epstein MA. HLA-restricted T-cell recognition of Epstein-Barr virus infected B-cells. Nature 1980; 283: 865-867.
19. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Celt 1994; 77: 791-793.
20. Gratama JW, Oosterveer MAP, Lepoutre JMM et al. Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients. Transplantation 1990; 49: 725-730.
21. Savoie A, Perpête C, Carpentier L et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715-2722.
22. Riddler SA, Breining MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972-984.
23. Labadie J, Tol MJD van, Dijkstra NH et al. Transfer of specific immunity from donor to recipient of an allogeneic bone marrow graft: effect of conditioning on the specific immune response of the graft recipient. Br J Haematol 1992; 80: 381-390.
24. Duncombe AS, Grundy JE, Oblakowski P et al. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood 1992; 79: 3059-3066.
25. Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function associated LFA-1, CD2 and LFA-3 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol 1987; 5: 223-252.
26. Tilkin AF, Bagot M, Dreyfus F et al. Reconstitution of cytotoxic T-lymphocyte activity following allogeneic bone marrow transplantation in man. Transplantation 1987; 44: 303-308.
27. Heslop HE, Congfen L, Krance RA et al. Epstein-Barr infection after bone marrow transplantation. Blood 1994; 83: 1706 (letter).
28. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118: 45-58.
29. Craig FE, Gutley ML, Banks PM. Post transplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265-276.
30. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analyses demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
31. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Lancet 1993; 341: 203-205.
32. Rooney CM, Loftin SK, Hollady MS et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103.
33. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
34. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. New Engl J Med 1994; 331: 679 (letter).
35. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1994; 345: 9-13.